Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems.
Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
January 4, 2021
Chinook Therapeutics to Present at Upcoming Investor Conferences
December 8, 2020
Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities